Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
Assay Type | Sandwich-ELISA |
Analyte | IL-6 |
Format | 96T(8×12 strips) |
Reactivity | Human |
Regulatory Status | RUO |
Sensitivity | <2.34pg/mL |
Standard Curve Range | 2.34 pg/mL-150 pg/mL |
Assay Time | 2 hr 50 min |
Suitable Sample Type | For the quantitative determination of human IL-6 in Cell Culture Supernatants, Plasma, Serum. |
Sample volume | 100 uL |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ID | Components | Size |
CRS005-C01 | Pre-coated Anti-IL-6 Antibody Microplate | 1 plate(8×12 strips) |
CRS005-C02 | Human IL-6 Standard | 20 μg |
CRS005-C03 | Biotin-Anti-IL-6 Antibody | 50 μL |
CRS005-C04 | Streptavidin-HRP | 50 μL |
CRS005-C05 | 10xWashing Buffer | 50 mL |
CRS005-C06 | 2xDilution Buffer | 50 mL |
CRS005-C07 | Substrate Solution | 12 mL |
CRS005-C08 | Stop Solution | 7 mL |
For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The following example data is for reference only.
To assess the linearity of the assay, samples spiked with high concentrations of human IL-6 were serially diluted with calibrator diluent to produce samples with values within the dynamic range of the assay.
Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision, Intra-Assay Precision CV<10%.
Three samples of known concentration were tested in three separate assays to assess inter-assay precision, Inter-Assay Precision CV<10%.
Three parts of blank serum were added with different concentrations of human IL-6, and the serum without human IL-6 was used as background to calculate the recovery rate. The range of the recovery rate is 90.6-114.8%, and the average recovery is 101.2%.
ACROBiosystemsは、二重特異性抗体の治療薬への臨床開発を加速するために、高い生物活性を持つ均一なCD3δ/CD3εおよびCD3γ/CD3εタンパク質のシリーズを開発しました。
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox は、即使用可能のオルガノイド、オルガノイド分化ツールキット、創薬プロジェクトの進行を加速する、さまざまなサービスを含むオルガノイドソリューションのことです。
IL-15、IL-7、IL-21など、高品質のGMP準拠サイトカイン製品を提供しており、免疫細胞治療薬の臨床研究をサポートし、医薬品規制当局の承認を加速できます。
注目されている50以上のCAR-Tターゲットがあり、CARの発現の検出のために設計された抗原タンパク質をフローサイトメトリーで検証し、CARの発現が高い特異性で検出できます。ロット間の一貫性が保証されています。また、PE / FITC標識タンパク質を利用することで、ワンステップ染色でCARの発現を高い特異性でバックグラウンドなしに検出できます。
CD20、Claudin18.2、CD133、GPRC5D、CCR5、CCR8などの安定で高活性な全長型膜貫通タンパク質は、免疫学、ELISA、SPR、BLI、細胞実験、CAR陽性率検出に利用できます。VLP、界面活性剤、ナノディスクなどのテクニカルプラットフォームによって複数回膜貫通タンパク質の医薬品創薬を促進できます。
GMP準拠サイトカイン、高品質の細胞活性化/増幅試薬、遺伝子改変試薬/酵素、CAR検出試薬などの製品を提供し、細胞、遺伝子治療用に全体的なソリューションを提供し、創薬から臨床研究までのすべての段階をサポートします。
これまでに知られている免疫チェックポイント分子をほぼ製品化しており、様々なタグの製品群を提供できます。天然高分子の構造はMALSによって、生物活性はELISA/SPR/BLI/FACSなどによって検証済みです。またBiotin/FITCなどの標識も選択でき、抗体のハイスループットスクリーニングに利用できます。
弊社ACROBiosystemsはADC医薬品の開発のサポートに取り組み、注目されている様々なターゲットのために、異なる種類とタグの製品が開発され、高い純度と親和性が特長です。免疫、抗体スクリーン、SPR、細胞活性検査などの実験に利用できます。Protocolも無償で提供いたします。
すべての分子のFc受容体タンパク質だけでなく、一般的な変異体やビオチン標識タイプも含まれております。お客様のモノクローナル抗体の開発をサポートします。
インターロイキン、成長因子、ケモカイン、TNF など、様々なサイトカインターゲットの自然なコンフォメーションを確保するために HEK293 によって発現されます。SDS-PAGE/HPLC/SEC-MALS によって高純度は確認され、高い生物活性は ELISA/SPR/BLI によって確認されています。
AneuroはACROBiosystemsが神経科学研究のために設計した製品群のブランドです。神経科学研究を推進するための治療・診断用研究タンパク質、PFF、組み換え神経因子など、高品質の重要なタンパク質を提供しております。
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; IMID-5013; CDC-5013; CDC-501 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo, Zelvina | United States | Myelodysplastic Syndromes | Bristol Myers Squibb Srlcompany | 2005-12-27 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Bone Marrow Neoplasms; Kidney Neoplasms; Leukemia, Myeloid; Leukemia; Intestinal Neoplasms; Craniopharyngioma; Optic Nerve Glioma; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Medulloblastoma; Ependymoma; Immunoproliferative Small Intestinal Disease; Leukemia, Erythroblastic, Acute; Hematologic Diseases; Liver Neoplasms; Plaque, Amyloid; Anemia; Pain; Paraproteinemias; Polycythemia Vera; Anemia, Refractory, with Excess of Blasts; Rhabdoid Tumor; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Hodgkin Disease; Graft vs Host Disease; Glioblastoma; Neoplasms; Blood Protein Disorders; Nerve Degeneration; Anemia, Refractory; Hypothalamic Neoplasms; Leukemia, Myelomonocytic, Acute; Pancreatic Neoplasms; Lymphomatoid Granulomatosis; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervou | Details |
Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis; Plaque psoriasis | Details | ||
Pomalidomide | CDC-394; CC-4047; IMiD-1; IMID-4047 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2013-02-08 | Lung Diseases, Interstitial; Neurofibromatosis 1; Atypical Squamous Cells of the Cervix; Sarcoma, Kaposi; Anemia, Sickle Cell; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Prostatic Neoplasms; Thrombocytosis; Sarcoma; Central Nervous System Neoplasms; Pulmonary Fibrosis; Medulloblastoma; Multiple Myeloma; Pancreatic Neoplasms; Hodgkin Disease; Plasmacytoma; Myeloproliferative Disorders; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Scleroderma, Systemic; Renal Insufficiency; Polycythemia Vera; Bone Marrow Neoplasms; Solid tumours; Optic Nerve Glioma | Details |
Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | United States | Multicentric Castleman's Disease (MCD) | Eusa Pharma | 2014-04-23 | Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Castleman Disease; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Lung Diseases; Multiple Myeloma; Respiratory Distress Syndrome, Adult; Bone Marrow Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Psychotic Disorders; Respiratory Tract Diseases; Smoldering Multiple Myeloma; Polycythemia Vera; Carcinoma, Renal Cell; Pneumonia; Schizophrenia; Diabetes Mellitus, Type 1; Ovarian Neoplasms; Cytokine Release Syndrome; Head and Neck Neoplasms; Respiratory Tract Infections; Kidney Neoplasms | Details |
Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Xerostomia; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Osteosarcoma; Cholangitis, Sclerosing; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Epilepsy; Erythema Nodosum; Sarcoma; HIV Wasting Syndrome; Pancreatitis, Chronic; Sarcoma, Ewing; Arachnoiditis; Gastrointestinal Hemorrhage; Retinoblastoma; Prostatic Neoplasms; Endometriosis; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Carcinoma, Hepatocellular; Burning Mouth Syndrome; Stomatitis; Neoplasm Metastasis; Appendiceal Neoplasms; Tuberculosis; Lymphoma, Non-Hodgkin; Angiodysplasia; Pelvic Pain; Glioma; Waldenstrom Macroglobulinemia; Leprosy, Lepromatous; Endometrial Neoplasms; Uterine Neoplasms; Anemia, Sideroblastic; Ovarian Neoplasms; Gastric Antral Vascular Ectasia; Lupus Erythematosus, Discoid; Carc | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Tissue Adhesions; Post-surgical adhesions; Cicatrix | Details |
Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Arthritis; Crohn Disease | Details |
Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | HIV Infections; Hematopoietic stem cell transplantation (HSCT); Solid tumours; Leukemia; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Dyslipidemias; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Melanoma | Details |
Ziltivekimab | COR-001; NN6018 | Phase 3 Clinical | Astrazeneca Plc | Heart Failure; Atherosclerosis; Anemia; Myocardial Infarction; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome | Details |
Clazakizumab | BMS-645429; ALD518-003; ALD-518; CSL300; BMS-945429; CSL-300 | Phase 3 Clinical | Alder Biopharmaceuticals | Cardiovascular Diseases; Stomatitis; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Diabetes Mellitus; Kidney Failure, Chronic; Cachexia; Asthma; Arthritis, Psoriatic; Plaque, Atherosclerotic; Rejection of organ transplantation; Graft vs Host Disease; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Atherosclerosis; Myocardial Infarction | Details |
Tabirafusp tedromer | KSI-501ABC; KSI-501 | Phase 3 Clinical | Kodiak Sciences Inc | Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Uveitis | Details |
Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics, Biovie Inc | Diabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Parkinson Disease; Colitis, Ulcerative | Details |
Vamikibart | RO-7200220; RG-6179; EBI-031 | Phase 3 Clinical | Sesen Bio Inc | Macular Edema; Diabetic macular oedema | Details |
Sodium Hypochlorite | Phase 3 Clinical | Cystic Fibrosis; Pulpitis; Infections; Pain; Pain, Postoperative; Fibrosis; Dental Pulp Necrosis | Details | ||
PF-04236921 | PF-04236921; TOUR006; TOUR-006; PF-4236921 | Phase 2 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Cardiovascular Diseases; Renal Insufficiency, Chronic; Crohn Disease | Details |
Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine | Depressive Disorder, Major; Giant Cell Arteritis; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
KSI-101 | KSI-501P; KSI-101 | Phase 2 Clinical | Kodiak Sciences Inc | Macular Edema | Details |
Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | BIOCAD JSC | Autoimmune Diseases | Details | |
Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Frailty; Hashimoto Disease; Depression; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
SCD-153 | SCD-153 | Phase 1 Clinical | Sun Pharma Advanced Research Company Ltd, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University | Alopecia Areata | Details |
NEX-20A | NEX-20A | Phase 1 Clinical | Nanexa AB | Multiple Myeloma | Details |
Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Wogonin | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Details |
This web search service is supported by Google Inc.